Medicaroid Attains Regulatory Clearance for the hinotori™ Surgical Robot System
Medicaroid Corporation and Medicaroid Asia Pacific Pte. Ltd. have announced that they have obtained regulatory clearance from the Health Sciences Authority in Singapore for the hinotori Surgical Robot System, which was granted on September 13.
The hinotori is a Japanese-made robotic-assisted surgical system that secured regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) in August 2020. Following its launch in December of the same year, it has been employed in numerous medical institutions, with over 2,000 procedures conducted.
In addition to their domestic operations in Japan, Medicaroid has been gearing up for expansion into the global market. To facilitate activities in Southeast Asia, Oceania, and South Asia, they established Medicaroid Asia Pacific Pte. Ltd., a subsidiary based in Singapore, in October 2022. On April 28, 2023, they submitted an application for regulatory clearance for the hinotori to the Health Sciences Authority (HSA), which was subsequently granted. This marks the first international regulatory approval for the hinotori.
In Singapore, the hinotori will be utilized in urology, gastroenterology, and gynecology procedures, as these are the same categories approved in Japan. With this green light, Medicaroid, in collaboration with Medicaroid Asia Pacific Pte. Ltd. and their primary distributor, Sysmex Corporation, will prepare for sales operations in the Singaporean market.
Through their medical robotic solutions, Medicaroid remains committed to fostering a society where patients, their families, and healthcare professionals can all enjoy a sense of security and well-being.
© Medicaroid Inc